Larry Dobrow

Most Recent Articles by Larry Dobrow

Top 3 formulary access takeaways for pharma

Top 3 formulary access takeaways for pharma

Here's three items you need to know from our latest managed markets/payer feature: Formulary Fireworks

Formulary Fireworks

Formulary Fireworks

In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of power may well have shifted—but not to the degree that many observers had predicted

Headliner: New Synta chief adds commercialization clout

Headliner: New Synta chief adds commercialization clout

Anne Whitaker, President and CEO, Synta Pharmaceuticals

Mobile Marketing Report: On Hold

Mobile Marketing Report: On Hold

It's not as though pharma marketers didn't see mobile coming. For the past half decade, they've discussed its potential to transform behaviors and relationships within the healthcare ecosystem. Yet now that mobile has arrived, they find themselves torn between caution and exuberance. Larry Dobrow explains

Headliner: Scientist CEO sets sights on Sierra Leone

Headliner: Scientist CEO sets sights on Sierra Leone

Thomas Sack, President and CEO, MRIGlobal

More Articles by Larry Dobrow

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters